RxDoctor Payments Data

Raymond Hernandez, MD

Ophthalmology · San Antonio, TXNPI 1881770915

Payments from drug & device makers

$3,804in general payments, 2019–2025

Across 103 payments — averaging $36.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$603
  • Amgen$546
  • Alcon$514
  • Biotissue Holdings Inc.$349
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$326
  • Tarsus Pharmaceuticals, Inc.$286
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,77999%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,804 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$232,546
Medicare patients
868
Services billed
2,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine90$105,639
LumiganBimatoprost93$60,460
XiidraLifitegrast37$57,327
Cyclosporine40$29,533
MieboPerfluorohexyloctane/Pf29$25,667
RhopressaNetarsudil Mesylate27$17,272
VyzultaLatanoprostene Bunod29$17,094
Travoprost94$16,873
CequaCyclosporine11$15,798
VevyeCyclosporine19$14,260
Latanoprost842$10,505
SimbrinzaBrinzolamide/Brimonidine Tart22$9,049
Alphagan PBrimonidine Tartrate16$8,015
RocklatanNetarsudil Mesylat/Latanoprost11$6,926
Brinzolamide23$6,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$166$174,113199 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan$603$105,018106 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$125$24,19838 claims
Sun Pharmaceutical Industries Inc.Cequa$111$15,79811 claims
Harrow Eye, LLCVevye$167$14,26019 claims
AlconSimbrinza$514$9,04922 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$326$2,65516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →